Challenges in mucosal vaccines for the control of infectious diseases

Tatsuhiko Azegami, Yoshikazu Yuki, Hiroshi Kiyono

Research output: Contribution to journalReview article

38 Citations (Scopus)

Abstract

The mucosal surface is the largest route through which pathogens enter the human body. To control the outbreak of mucosal infectious diseases, we must use our knowledge of the mucosal immune system to create vaccines that elicit protective mucosal and systemic immunity. Mucosal vaccines have advantages over traditional injectable vaccines in that they not only induce effective mucosal immune responses, but they also do not cause physical or psychological discomfort. Mucosal vaccines currently licensed for human use include oral vaccines against Vibrio cholerae, Salmonella typhi, poliovirus and rotavirus, and nasal vaccines against influenza virus. To further improve the existing vaccines, it will be necessary to develop novel vaccine production, storage and delivery systems through innovative strategies derived from interdisciplinary scientific research. Our accumulated knowledge of the innate and acquired arms of the mucosal immune system and the recent scientific and technical advancements in the fields of molecular biology, plant biology, bio-engineering and chemical engineering, genome biology and systems biology have created a unique research and development platform for the development of the next generation of mucosal vaccines. This review summarizes the current perspectives and future directions of mucosal vaccine development with emphasis on oral and nasal vaccines for the control of infectious diseases.

Original languageEnglish
Article numberdxu063
Pages (from-to)517-528
Number of pages12
JournalInternational Immunology
Volume26
Issue number9
DOIs
Publication statusPublished - 2014

Fingerprint

Communicable Diseases
Vaccines
Mucosal Immunity
Nose
Immune System
Chemical Engineering
Rotavirus Vaccines
Bioengineering
Salmonella typhi
Vibrio cholerae
Systems Biology
Poliovirus
Orthomyxoviridae
Human Body
Research
Disease Outbreaks
Molecular Biology
Genome
Psychology
Injections

Keywords

  • MucoRice
  • Nasal vaccine
  • Oral vaccine
  • Rice-based vaccine

ASJC Scopus subject areas

  • Immunology
  • Medicine(all)

Cite this

Challenges in mucosal vaccines for the control of infectious diseases. / Azegami, Tatsuhiko; Yuki, Yoshikazu; Kiyono, Hiroshi.

In: International Immunology, Vol. 26, No. 9, dxu063, 2014, p. 517-528.

Research output: Contribution to journalReview article

Azegami, Tatsuhiko ; Yuki, Yoshikazu ; Kiyono, Hiroshi. / Challenges in mucosal vaccines for the control of infectious diseases. In: International Immunology. 2014 ; Vol. 26, No. 9. pp. 517-528.
@article{ca8db58f8d1b4847b06fbac35d7e17f8,
title = "Challenges in mucosal vaccines for the control of infectious diseases",
abstract = "The mucosal surface is the largest route through which pathogens enter the human body. To control the outbreak of mucosal infectious diseases, we must use our knowledge of the mucosal immune system to create vaccines that elicit protective mucosal and systemic immunity. Mucosal vaccines have advantages over traditional injectable vaccines in that they not only induce effective mucosal immune responses, but they also do not cause physical or psychological discomfort. Mucosal vaccines currently licensed for human use include oral vaccines against Vibrio cholerae, Salmonella typhi, poliovirus and rotavirus, and nasal vaccines against influenza virus. To further improve the existing vaccines, it will be necessary to develop novel vaccine production, storage and delivery systems through innovative strategies derived from interdisciplinary scientific research. Our accumulated knowledge of the innate and acquired arms of the mucosal immune system and the recent scientific and technical advancements in the fields of molecular biology, plant biology, bio-engineering and chemical engineering, genome biology and systems biology have created a unique research and development platform for the development of the next generation of mucosal vaccines. This review summarizes the current perspectives and future directions of mucosal vaccine development with emphasis on oral and nasal vaccines for the control of infectious diseases.",
keywords = "MucoRice, Nasal vaccine, Oral vaccine, Rice-based vaccine",
author = "Tatsuhiko Azegami and Yoshikazu Yuki and Hiroshi Kiyono",
year = "2014",
doi = "10.1093/intimm/dxu063",
language = "English",
volume = "26",
pages = "517--528",
journal = "International Immunology",
issn = "0953-8178",
publisher = "Oxford University Press",
number = "9",

}

TY - JOUR

T1 - Challenges in mucosal vaccines for the control of infectious diseases

AU - Azegami, Tatsuhiko

AU - Yuki, Yoshikazu

AU - Kiyono, Hiroshi

PY - 2014

Y1 - 2014

N2 - The mucosal surface is the largest route through which pathogens enter the human body. To control the outbreak of mucosal infectious diseases, we must use our knowledge of the mucosal immune system to create vaccines that elicit protective mucosal and systemic immunity. Mucosal vaccines have advantages over traditional injectable vaccines in that they not only induce effective mucosal immune responses, but they also do not cause physical or psychological discomfort. Mucosal vaccines currently licensed for human use include oral vaccines against Vibrio cholerae, Salmonella typhi, poliovirus and rotavirus, and nasal vaccines against influenza virus. To further improve the existing vaccines, it will be necessary to develop novel vaccine production, storage and delivery systems through innovative strategies derived from interdisciplinary scientific research. Our accumulated knowledge of the innate and acquired arms of the mucosal immune system and the recent scientific and technical advancements in the fields of molecular biology, plant biology, bio-engineering and chemical engineering, genome biology and systems biology have created a unique research and development platform for the development of the next generation of mucosal vaccines. This review summarizes the current perspectives and future directions of mucosal vaccine development with emphasis on oral and nasal vaccines for the control of infectious diseases.

AB - The mucosal surface is the largest route through which pathogens enter the human body. To control the outbreak of mucosal infectious diseases, we must use our knowledge of the mucosal immune system to create vaccines that elicit protective mucosal and systemic immunity. Mucosal vaccines have advantages over traditional injectable vaccines in that they not only induce effective mucosal immune responses, but they also do not cause physical or psychological discomfort. Mucosal vaccines currently licensed for human use include oral vaccines against Vibrio cholerae, Salmonella typhi, poliovirus and rotavirus, and nasal vaccines against influenza virus. To further improve the existing vaccines, it will be necessary to develop novel vaccine production, storage and delivery systems through innovative strategies derived from interdisciplinary scientific research. Our accumulated knowledge of the innate and acquired arms of the mucosal immune system and the recent scientific and technical advancements in the fields of molecular biology, plant biology, bio-engineering and chemical engineering, genome biology and systems biology have created a unique research and development platform for the development of the next generation of mucosal vaccines. This review summarizes the current perspectives and future directions of mucosal vaccine development with emphasis on oral and nasal vaccines for the control of infectious diseases.

KW - MucoRice

KW - Nasal vaccine

KW - Oral vaccine

KW - Rice-based vaccine

UR - http://www.scopus.com/inward/record.url?scp=84906829681&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84906829681&partnerID=8YFLogxK

U2 - 10.1093/intimm/dxu063

DO - 10.1093/intimm/dxu063

M3 - Review article

VL - 26

SP - 517

EP - 528

JO - International Immunology

JF - International Immunology

SN - 0953-8178

IS - 9

M1 - dxu063

ER -